RESEARCH ARTICLE

A systematic literature review of individuals’ perspectives on privacy and genetic information in the United States

Ellen W. Clayton1,2,3*, Colin M. Halverson1*, Nila A. Sathe4**, Bradley A. Malin3,5,6**

1 Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, TN, United States of America, 2 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States of America, 3 Center for Genetic Privacy & Identity in Community Settings, Vanderbilt University Medical Center, Nashville, TN, United States of America, 4 Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, and Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, United States of America, 5 Departments of Biomedical Informatics and Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States of America, 6 Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville, TN, United States of America

☯ These authors contributed equally to this work.
¤ Current address: Premier Applied Sciences, Charlotte, NC, United States of America
* Ellen.clayton@vanderbilt.edu

Abstract

Concerns about genetic privacy affect individuals’ willingness to accept genetic testing in clinical care and to participate in genomics research. To learn what is already known about these views, we conducted a systematic review, which ultimately analyzed 53 studies involving the perspectives of 47,974 participants on real or hypothetical privacy issues related to human genetic data. Bibliographic databases included MEDLINE, Web of Knowledge, and Sociological Abstracts. Three investigators independently screened studies against predetermined criteria and assessed risk of bias. The picture of genetic privacy that emerges from this systematic literature review is complex and riddled with gaps. When asked specifically “are you worried about genetic privacy,” the general public, patients, and professionals frequently said yes. In many cases, however, that question was posed poorly or only in the most general terms. While many participants expressed concern that genomic and medical information would be revealed to others, respondents frequently seemed to conflate privacy, confidentiality, control, and security. People varied widely in how much control they wanted over the use of data. They were more concerned about use by employers, insurers, and the government than they were about researchers and commercial entities. In addition, people are often willing to give up some privacy to obtain other goods. Importantly, little attention was paid to understanding the factors—sociocultural, relational, and media—that influence people’s opinions and decisions. Future investigations should explore in greater depth which concerns about genetic privacy are most salient to people and the social forces and contexts that influence those perceptions. It is also critical to identify the social practices that will make the collection and use of these data more trustworthy for participants as well as to identify the circumstances that lead people to set aside worries and decide to participate in research.
Introduction

Genomics research often requires gathering data about genomic variation, phenotypes, demographics, and exposures from large numbers of people. Research using these data has the potential to uncover the contributions of genomic variants to human health and disease and provides a powerful tool for understanding how individuals’ life experiences affect outcomes. Discoveries can then be leveraged to develop more refined clinical care to improve individuals’ health, as already occurs in pharmacogenomics, [1–4] cancer diagnosis and therapy, [5] and solving previously undiagnosed diseases. [6–8]

In order to create sufficiently large collections of data for this type of research, investigators who plan to collect genomic, as well as other types of, data using funding from the U.S. National Institutes of Health (NIH) are now required—in almost all cases—to obtain express consent from participants for broad data sharing, which provides other investigators the freedom to use the data for a wide array of research endeavors without seeking additional consent. [9] As of 2017, the U.S. Common Rule, which regulates research with human subjects, now, for the first time, endorses broad data sharing as an acceptable option. [10] Despite significant public support for broad data sharing for research, [11] not all people in the United States are willing to allow genomic, and other related, data about themselves to be used for this or other purposes.[12, 13] One particularly prominent concern that people indicate is that uses of data about them for research impinge on their privacy. Privacy, however, is a multifaceted concept [14] that is often used by investigators and research subjects alike in a merely vaguely defined way—if they define it at all. Thus, it is necessary to parse various concepts encompassed by the expansive term of privacy to understand what underlies their apprehension.

The multiple connotations of privacy vary significantly in their implications for genomics research. One view of privacy is solitude, which is simply the desire to be “let alone.” [15] Privacy, at times, also refers to anonymity, or the wish not to be identified or otherwise made known to be a member of a group or class of persons. [16] A related concept that is frequently conflated with privacy is confidentiality, whereby a person can share information without making it widely available if the recipient, such as a primary care physician or psychotherapist, is legally or ethically obligated to keep secret what has been communicated to them by the sharer. [17] While privacy and confidentiality are analytically quite distinct, these terms are often used interchangeably in research settings [18, 19] and in casual conversation. This is a concern as the conflation has the potential to create confusion and a lack of clarity in characterizing individuals’ views about genetic privacy. These three notions—the desire to be let alone, to be anonymous, and to be protected by confidentiality—relate to how a person expects to be treated or regarded and so can be thought of as dignitary interests.

Dignitary concerns are not all that is at stake in discussions of genetic privacy. People also worry that genomic data about them will be used to ends with which they do not agree [20] or which might even harm them. In this respect, they are particularly concerned that data will be exploited to deny them, or those they love, access to important goods of life, such as employment and insurance. [21] As a result, people often seek to control how data about them are used and express worries about the efficacy of the affiliated governance and data security routines set in place. They do this even though examples of misuse and harm have been hard to come by, calling into question whether worries about widespread misuse and discrimination are well-founded. [22, 23] Nonetheless, concerns about potential harms have been a major topic of investigation and commentary. [24–26]

Understanding what people are worried about when they express their concerns in the phrase genetic privacy is an essential step toward developing strategies to take their concerns into account and, if possible, to allay them when developing organizational practices, setting
policy in the United States, and designing privacy enhancing technologies. In order to learn what is already known and to identify additional empirical research questions whose answers could help inform policy development, we performed a systematic review of the qualitative and quantitative studies that have been conducted to date that have explored individuals’ views about the many aspects of genetic privacy in the context of clinical care and genetic research, as well as the demographic characteristics with which those concerns have been associated.

As will be illustrated in depth throughout this article, we discovered that research to date reveals a complex, but also incomplete, picture of what people think about genetic privacy. This is partially an artifact of the observation that the studies varied widely in what issues they explored. For instance, some studies asked simply whether people worried about genetic privacy, while others were more nuanced about the specific aspects of privacy they inquired about. The issues most frequently explored were opinions about how other people might use genetic information about an individual. In general, researchers were often thought to be trustworthy, especially if they were associated with the institution where the person sought care as a patient, while people worried about what employers, insurers, and the government would do with the data. Less attention was paid to the value of informed consent, access control, and governance, including the efficacy of legal protections. Respondents were rarely asked about re-identification risk (i.e., ascertaining the personal name or contact information of the individual to whom genetic data, devoid of identifiers, correspond) despite its prominence in policy debates in the United States and elsewhere, especially as compared with the greater frequency with which concerns about already identified data were probed. Of particular note, very little was asked about the social factors and relationships that often influence opinions. Still, despite the lack of detail about what people think about genetic privacy, a growing number of publications reveal that many people are willing to forgo some privacy to obtain genetic information and to promote research.

Results

Article selection and overview

Our search retrieved 6,985 citations, 4,521 (64.7%) of which were triaged by the automated algorithm as not likely providing empirical data. Among the remaining 2,464 studies that were manually screened, 203 (8.2%) studies (reported across 217 publications) met our inclusion criteria and addressed aspects of privacy. However, the majority focused only on aspects of discrimination and so were excluded from further analysis. Fifty publications addressing broader perceptions of privacy as a major focus were supplemented by three additional articles following a manual search in July 2017, and it is these publications that are the subject of this review. (Fig 1 and S1 Table) Most studies (n = 36) were published between 2010 and 2017. We rated 4 studies as good, [12, 27–29] 35 studies as fair, [16, 18, 19, 28, 30–63] and 14 as poor quality. [62–76] (S2 Table) Studies with poor methodologic quality typically did not provide as much detail about personal views, but were retained to illustrate what has been explored in previous research.

The studies explored the responses of a total of 47,974 participants. Surveys including those in mixed methods studies were administered to 42,754 respondents, while a number of different qualitative approaches involved 11,327 participants. Eighteen studies, involving 35,323 respondents, explored the views of the general public and direct to consumer users. By contrast, 31 studies, involving 11,621 respondents, focused on patients, their families and surrogate decision makers, as well as research participants. The remainder of the studies reported on the views of clinicians, researchers, institutional review boards (IRBs), and journal editors, representing a different set of stakeholders. Observations from the latter studies are presented after those of the public, patients, and research participants.
Studies typically focused on specific contexts, such as genetic research generally (n = 13), biobanking or specimen donation (n = 17), with two studies reported in one publication. Twelve studies focused on clinical genetics (including genetic testing and whole genome sequencing (WGS)), [19, 35–37, 42, 58, 59, 66, 67, 69, 72, 73] Most studies addressed views of the general public [35, 59, 72] or patients. [36, 37, 42, 69, 73] Three addressed direct-to-consumer (DTC) genetic testing. [18, 56, 67] Most addressed hypothetical questions about what people thought rather than decisions about genetic testing that people had experienced.

Of the studies reporting data regarding sex of the general public/patient participants (n = 41,519 participants), 26,656 (64%) were female. None addressed gender identity as distinct from reported sex. Across the 39 studies reporting data on race or ethnicity (n = 38,736 participants), 24,566 participants who completed participation identified themselves as White or Caucasian (63%), 6,430 as Black or African-American (17%), 3174 as Hispanic (8%), and 4511 as other (12%), a category which includes Asian and Native Americans and many other ethnic groups, as described in Fig 2.
Issues explored in the studies

As noted earlier, the investigators of this review developed a set of categories to apply to these studies, including whether one’s data or identity is known, control, downstream use and users, and tradeoffs between privacy and services or goods. Researchers varied widely in the specific issues they explored in their studies as described in Fig 3.

Whether one is known. General concerns about privacy. Investigators frequently asked about the general level of concern about privacy without eliciting further details about the respondents’ reasons for concern. [12, 19, 27, 29, 31, 35, 37–39, 44, 45, 49, 51, 59, 66, 70, 78] Some investigators focused solely on concerns about genomic information, [43, 54, 66, 79] while other researchers studying questions of privacy and genetics asked about the privacy of medical information generally either in lieu of, or in addition to, genetic data. [16, 28, 29, 42, 45, 52, 53, 56, 63, 67] For example, a survey of 13,000 patients at medical centers involved in the NIH-sponsored Electronic Medical Records and Genomics (eMERGE) consortium, which focused on consent and data sharing for genomics research, indicated that 11,397 (90%) agreed that “health information” privacy was important and that 8,135 (64%) were worried about this type of privacy. [12] In a mixed methods study conducted at Mt. Sinai Medical Center in New York City, 20 (57%) of the 35 healthy respondents who had undergone whole genome sequencing endorsed concerns about unspecified potential privacy issues in closed-ended questions. [34] A survey including 1,253 patients with bipolar disorder asked about “loss of privacy” among other issues. [49] A survey of 304 African-Americans in the Washington, DC, area revealed that 259 respondents (85%) were willing to undergo genetic testing for susceptibility to
Fig 3. A summary of the number of articles that addressed each of the topics discovered in the systematic literature review.

https://doi.org/10.1371/journal.pone.0204417.g003
alcohol dependency, but 91 (30%) of participants had unspecified privacy concerns. Notably, these individuals indicated that, in general, they were more concerned about being labeled by their physicians than by family members. [19] Thirteen of 100 breast cancer patients (13%) at M.D. Anderson Cancer Center in Houston, Texas expressed significant concerns about a composite measure of “genomic data privacy.” [42] These studies, which all relied, at least in part, on surveys, may have prompted the respondents’ concern by their specific questions.

In some qualitative studies, few respondents volunteered worries about privacy when not specifically prompted. [36] In a study interviewing 65 parents of children being seen at primary care or multispecialty clinics at Vanderbilt University Medical Center, 21 (32%) endorsed privacy concerns when prompted, but none raised the issue on their own. [68] Similarly, a focus group study of women with breast cancer who had previously donated tissue at the Dana-Farber Cancer Institute similarly reported few privacy concerns—even when prompted—with two participants commenting that privacy protections might even hamper research. [71]

Concern that individuals might be identified was a commonly explored topic. [16, 27–29, 31, 35, 38, 52–54, 62–64, 72, 79–81] Almost half of the surveyed breast cancer patients at M.D. Anderson were concerned about having their name associated with their genomics results. [42] Additionally, some participants in the open access Personal Genome Project expressed mixed feelings about being identified even though they were told that their privacy could not be guaranteed. [62] By contrast, a number of studies reported that respondents were not particularly worried about the identifiability of their genetic information. [27, 30, 47, 50] Cancer patients in the Participant Issues and Expectations Project survey in Washington state were more worried about having their financial information stolen than their genetic data (69% vs. 3%). [30] Interestingly, only six studies explicitly explored whether people were worried about being re-identified from their DNA. [30, 31, 46, 47, 62, 81] In one study, parents were not worried about being re-identified from DNA because their affected children had a particular genetic syndrome with distinctive physical manifestations, such that they were under the impression that they were so readily identifiable anyway. [69] Far from desiring anonymity, some respondents wanted to ensure that they could be identified so they could receive research results. [29, 30, 34, 41, 79]

Studies typically revealed the fewest insights about reasons other than discrimination why people were worried that information about them would be revealed. In one study some respondents cited philosophical or religious reasons for their privacy concerns. [16, 56] A few studies examined both family and personal privacy. [32, 36, 37] Sometimes, concepts were conflated in ways that limited insight. In particular, privacy and confidentiality were often used interchangeably by both investigators and respondents. [32, 52, 73] As noted above, these refer to distinct and non-commensurate concepts. In other studies, these distinctions were made clear to the respondents. [33]

**Control. The roles of consent for and personal control of data.** Questions about various aspects of privacy were often explored in the studies that addressed acceptable approaches to informed consent and control of genomic data. [12, 18, 27, 28, 31, 33, 39, 42–48, 50, 52–54, 62, 63, 66–68, 71, 73, 74, 78, 82] For example, in one study in which IRB professionals, researchers, and participants were asked to identify which statements were most important to include in consent forms, opinions varied widely. The importance of getting consent for the release of identifying information was the only one endorsed in the top ten statements by all the respondents. [50]

Concerns about privacy were correlated with desires for more focused consent. In a study addressing consent for biobanking, those who believed that it is not possible to maintain their privacy and those who did not limit their Internet use because of privacy concerns were less likely to agree to broad consent for use of data about them with oversight for unspecified
future research. In one survey of a mixed group of stakeholders including participants in a cancer registry, their family members, and self-referred individuals with and without cancer, participants who perceived greater risks associated with genetic data were more likely to agree that re-consent to the use of data about them should be mandatory (p = 0.003). One particular question often raised in the context of consent was how much control participants should have over the downstream use of data and samples obtained from them. In a study interviewing 18 self-designated early adopters of genome sequencing and health devices (participants in the Personal Genome Project; attendees of the Genomes, Environments, and Traits conference; or participants in the Health Data Exploration project), all (100%) wanted control over their own data, including control over whether or not to authorize dissemination. In a study interviewing parents of pediatric patients, family members and adult participants from cancer genomics studies (total n = 336), participants’ concerns included a lack of control over (mis)use and who could access their information in the public domain. In a focus group study including 15 participants in a Baylor College of Medicine study of epilepsy gene resequencing, participants had mixed views regarding ownership and sharing of data. Thirteen out of 15 (87%) participants wanted to maintain control over sharing, and most were concerned about privacy risks associated with public data release. Many opposed full public release of their DNA, and all (100%) opposed sharing with employers or insurance companies.

Notably, desire for ongoing control was not universal. Respondents in several studies were willing to cede decision making to IRBs and other oversight bodies. This willingness to give up control was particularly evident in the studies demonstrating support for broad data sharing. The roles of oversight, governance, and protection. Of the studies that explored views about the importance of governance, particularly regarding the use of data for research, some conflated oversight and security. In a focus group study (n = 49) including both participants in the NUgene biobank of Northwestern University Medical Center and the general public, roughly half of both groups (56% and 46%, respectively) were somewhat or very concerned about “[h]ow well . . . the privacy of individual genetic research data is protected.” Participants noted the importance of explicit privacy and security safeguards, oversight by a trustworthy institution, and penalties for misuse as important prerequisites for data sharing.

Participants in several studies were skeptical that governance would be effective. In a number of studies, some respondents simply felt that privacy could not be protected. In one nationwide online survey of English- and Spanish-speaking adults using Knowledge Network assessing views about genetic biobanks, of the 3,061 participants, roughly two-thirds, agreed that “maintain[ing] privacy is not possible” (1779 participants or 60%) or that privacy breaches are “inevitable” (1880 participants or 64%). Almost 1100 (37%) expressed concerns about the privacy of their medical information. As we have demonstrated commonly occurs, some of these questions failed to distinguish between privacy and security.

While some studies revealed doubt about the efficacy of data protection by health care institutions, in a survey of 1,046 individuals who had purchased DTC genetic testing, most users had positive perceptions of privacy protections provided by the company. Specifically, 1004 individuals (96%) agreed that “In thinking about [the company’s] service, I am confident my privacy has been protected,” and 377 individuals (36%) felt that their test data was better protected than data in the medical record (398 individuals (38%) felt protections were similarly well protected; 41 individuals (4%) felt data were less protected; 241 individuals (23%) were unsure).

Patients’ and the public’s views about the potential efficacy of legal protections were rarely probed. Of the 36 studies published since 2010—two years after the highly publicized enactment of the Genetic Information Nondiscrimination Act (GINA), which limited some uses of
genetic data in health insurance and employment—only six reported individuals’ views about this law. [83] Individuals at risk for hereditary cancer participating in focus groups were skeptical of the protection provided by GINA, while researchers thought these patients were well informed, evidently thinking that patients should be reassured. [41] Some potential participants in the MedSeq project, which offered whole genome sequencing to healthy patients as well as those with cardiomyopathy as part of clinical care, were aware of the limitations of GINA, perhaps because these were addressed in the consent process. [63] In another study, 2,363 (79%) respondents from the general public agreed that this law made them “feel more comfortable that genetic information collected in the study could not be used against” them. [27] This finding led these investigators to recommend that biobanks clarify the limits of this law during the consent process. The potential protection provided by the Health Information Portability and Accountability Act (HIPAA), the Americans with Disabilities Act (ADA), bans on preexisting condition limits in health insurance, privacy torts, and state privacy laws were not reported at all.

**Opinions about particular downstream users.** A major concern expressed about identified genomic data was that some third party would misuse this information. Many studies, as noted below, examined respondents’ views—both positive and negative—about a host of downstream users. Often, these questions focused—at least in part—on whether downstream users might use these data in ways that the participants would not agree with or in a manner that would harm them. What opinions researchers are interested in has varied over time. For example, investigators have explored respondents’ concerns about use of genetic information by employers and insurers for the last thirty years, but they have probed views about government use of these data for only about the last decade.

**Researchers, academic medical centers, and other nonprofit institutions in the United States.** Investigators frequently asked specifically about how much people trusted researchers themselves as opposed to the entities in which they work. Respondents in 14 studies generally reported that they trusted researchers in the United States. [12, 30, 31, 33, 38, 42, 47, 48, 53, 56, 65, 69, 74, 79] Some participants expressed more trust in researchers in the institution where they seek medical care than they do in researchers at other academic institutions. [33, 42] In eight studies, most participants expressed trust in their own health care institutions when asked, including patients who were cared for at eMERGE consortium academic medical centers (AMCs) as a group, [12] Group Health Cooperative of Puget Sound, [52, 67] M.D. Anderson, [42] Northwestern University Medical Center, [54] Dana-Farber Cancer Institute, [71] and Vanderbilt University Medical Center. [68] In a population-based survey of 639 individuals living in Nashville regarding BioVU, a biobank at Vanderbilt, 603 (88.8%) of respondents were somewhat or very confident that their “identity is protected when genetic information is used for research”, while 36 (11.2%) indicated that they were only a little or not at all confident. Additionally, 590 (93.9%) agreed that a DNA biobank is “fine as long as participants can choose whether to have their data included.” Similarly, 3,713 (92.2%) faculty and staff surveyed at Vanderbilt University were confident that the medical center adequately protected information. 3,766 (93.3%) endorsed the establishment and use of databanks when identifying information is removed; and 3,682 (91.6%) endorsed de-identified databanks, so long as research is approved by an ethics review board. [28] In other studies, some participants expressed trust in AMCs and non-profits more generally. [41] In one study, only 20 of 100 (20%) cancer patients at M.D. Anderson were concerned about the privacy protection offered by research institutions. [42] Condit and colleagues [31] asked participants in the Northwest Cancer Genetics Registry how important trust in the researcher and the institution was to them, combining those ratings with answers about benefits and risks to create a composite trust score. Respondents in other studies, however, stated
that they did not trust these institutions to protect their data. [43, 56] More than 11,000 (86%) respondents in a study of patients at the eMERGE institutions wanted to know if data were misused by researchers. [12] In another study with 931 U. S. veterans, almost all (97%) said that there should be a research agreement with the investigators with serious consequences in the event of breach. [29] Indeed, one study of users of DTC genetic tests found that this group trusted the companies more than they trusted their health providers and institutions to protect their information. [67]

Use by employers and insurers. The issue most frequently explored by investigators was participants’ worries about use of genetic and health information by insurers and employers. Of these, 31 reported that concerns about employers or insurers often were a significant concern. [12, 16, 18, 19, 28, 32, 35, 36, 38, 41, 43, 45, 47, 49, 50, 52, 54–56, 58, 59, 62–64, 66, 67, 70, 71, 74, 76, 79] For example, in a study of patients at a Northwestern University Medical Center-affiliated site who had contributed data to the NUgene biobank, roughly 30% to 60% of respondents identified potential risks of employer and insurance discrimination. [54] In a study interviewing 18 early adopters of genome sequencing and health devices, many were concerned about discrimination in insurance and employment. [62] Of 413 patients seen at Yale University outpatient cancer clinics who were asked about their interest in genomic tumor profiling, 198, 169 individuals (48,41%) were concerned about negative health or life insurance effects. [36] In a mixed methods study conducted at Mt. Sinai Medical Center, 10 of the 35 (29%) healthy respondents who had undergone whole genome sequencing worried about insurance discrimination. [34]

Evincing an even greater level of disapproval, participants in two studies reported that they thought that employers or insurers should not have access to genetic information for any purpose. In a survey of 1,046 individuals who had purchased DTC genetic testing, 1004 individuals (96%) of respondents felt that employers or insurers should not have access to the data. [67] Of the 931 U.S. veterans surveyed, 810 individuals (87%) felt it should be illegal for insurers or law enforcement to have access to the database. [29]

Other studies relayed that at least some of their respondents were not particularly concerned about whether their employers or insurers had access to their genetic information. [42, 68, 72] Some reported that their level of concern was mitigated to some extent either because 1) they were already sick or 2) they believed the nature of their job or social situation provided some protection. [63] Parents of pediatric patients, family members, and adult participants from cancer genomics studies (total n = 336) who had viewed an experimental consent form regarding public data sharing worried about identity theft and were more concerned about having their identity revealed than they were about health insurance discrimination. [38, 47, 48]

Commercial entities. Eight studies reported respondents’ thoughts about sharing their information with commercial entities, such as pharmaceutical companies. [30, 38, 43, 45, 47, 52, 58, 59, 72] For example, 44 of 100 (44%) patients at M.D. Anderson worried more about protection of privacy by drug companies than by research institutions or the government. [42] Respondents in another study, by contrast, felt that this was not a major reason for their decision not to take part in a biobank, [56] while participants in two other studies were confident that companies protected their privacy. [35, 67]

Government. Participants in 20 studies reported worries about providing access to genetic information to the government. [29–31, 35, 38, 40, 43, 46, 47, 52, 54–56, 58, 62, 67, 72, 73, 79] Use by law enforcement was specifically explored in two studies. One Michigan focus group study reported that some participants noted concerns about potential stigmatization by law enforcement. [45] In a particularly nuanced survey of 1,046 individuals who had purchased DTC genetic testing, 931 individuals (89%) felt it was very or somewhat “important that it be illegal for law enforcement to get their information.” [67] (at 426)
A gradient of trust in different users. Although one can infer from these studies that some genetic data recipients are seen to be more protective of their privacy than others, some investigators asked respondents to address this issue directly. [29, 52] One nationwide survey study, which defined privacy as “a condition where others have limited access to information about you” and security as “the protections that are in place to keep your information from being seen by people who do not have permission,” reported that of the 1,319 respondents, 646 individuals (49%) did not trust researchers outside of the U.S. to keep their health information private or secure, while roughly 330 individuals (25%) did not trust U.S. researchers to do the same. [33] Rogith and colleagues assessed M.D. Anderson breast cancer patients’ willingness to share identified or de-identified genomic data under different conditions. [42] They reported the following gradient in respondents’ willingness to share that applied no matter whether or not the research offered direct benefit or used identified data: (physician involved in their care) > (physician at M.D. Anderson) > (any cancer researcher) > (any researcher) > (anyone).

The role of trade-offs—to what extent are people willing to forgo some privacy in order to receive other goods. Despite potential privacy concerns, many people were still willing to proceed with genetic testing in research or the clinic. [19, 29] A particularly detailed study interviewed parents of pediatric patients, family members, and adult participants from cancer genomics studies (n = 229) who had viewed an experimental consent form regarding public data sharing. Respondents stated concerns about having their identity revealed, “the lack of control over who could access their information in the public domain, fear of identity theft, anxiety about government access, apprehension over the potential commercialization of their DNA, and fear that their data would be used in morally objectionable research.” [47] The majority nonetheless endorsed both protecting privacy (84%) and advancing research (74%), and two-thirds indicated the advancement of research was the more important when forced to choose between the two options. Individuals enrolling in the MedSeq study expressed concerns about privacy, but were more confident in the study’s security and persuaded about the benefits of taking part. [63] In an earlier study interviewing African-American oncology patients, 34% of the 196 leaned toward enrollment in a genetic research study, even though they felt that their information would not be kept private. [65]

Some respondents were quite enthusiastic about participating and even impatient with slowing research. A focus group study of 26 women with breast cancer reported few privacy concerns even when prompted, with 2 (8%) participants commenting that privacy protections might hamper research. [71] One group of parents whose children had phenylketonuria (PKU) or leukemia felt that getting information was more important than protecting privacy. [39] Some participants offered strategies to reassure those considering genetic testing. In one focus group study including 35 North Carolina residents, respondents felt that privacy concerns about research participation could be mitigated by transparent communication about who would have access to their data and explicit security measures, particularly for how their blood would be handled. [64]

In other studies, however, worries about privacy led people to decide not to participate in research. [32] The main reason why 34 of 310 (11%) respondents invited to participate declined to enroll in the Kaiser Permanente Northwest biobank was concern about privacy and confidentiality. [56] Of the 173 (46%) of invitees who actively declined enrollment in MedSeq, 14 (8%) cited privacy concerns as a reason not to participate, including worries about hacking, security, and discomfort with having results in their medical record, while 48 (28%) cited fear of insurance discrimination and 22 (13%) worried about the psychological impact of the results. [63] Similarly, in one nationwide survey, most parents were interested in WGS of
newborns, but the majority stated that the child’s privacy and the possibility of discrimination were very important. [66]

**Drivers of privacy concerns.** As we review below, most studies that reported information about potential drivers of concern assessed demographic factors such as race and age, attitudes toward risk or research, and trust orientation. Among studies evaluating demographic factors, non-White race and younger age were typically associated with greater privacy concerns or perceived risks. Associations of responses with other factors generally were not consistent.

**Race/ethnicity.** In almost all studies reporting differences in perspectives by race or ethnicity, non-White individuals had greater concerns about privacy, including more desire for control over use of their data and less willingness to share data than their White counterparts. In a survey including 1,253 patients with bipolar disorder that asked about “loss of privacy,” Blacks were more likely to be very concerned about loss of privacy as compared with Whites (41.9% vs. 24.6%, p < 0.0001). [49] In one study assessing perspectives about the use of residual bloodspots and including viewing of an educational movie about genetics research, African-American race, residence in Mountain states, and viewing an educational movie about retention and use of specimens were associated with a desire for notification about future use of the samples in research (p ≤ 0.05). [44] Among respondents willing to donate samples for genetic research (n = 1113) in another study, more African-Americans than Whites noted potential discrimination as a significant factor in reduced willingness to donate (64% vs. 36% White, p < 0.0001). [16, 53, 61] African-Americans were also less likely to accept broad consent vs. Whites (69% vs. 81%, p-value was not significant in adjusted analyses) in a study evaluating biobanking and consent preferences. [27] African-Americans were more likely to be unreceptive to genetic research (35.8% vs. 14.6%, p-value not reported), more likely to consider loss of confidentiality, genetic information being given to insurance companies, and genetic information-related discrimination to be major worries. [32] These reservations are not new, as African-Americans at the turn of the millennium were in one study more likely than Whites to have an initial negative reaction to news about the near-completion of the Human Genome Project (66.7% vs. 34.6% among Whites, p < 0.001) but not more likely to note privacy concerns. [74]

Non-White race was not a significant factor influencing privacy-related concerns in three studies. In one survey of 13,000 people, race and ethnicity were no longer statistically significant in determining views of data sharing once attitudes about research and biobanking were taken into account. [12] Asian and other ethnicities were associated with allowing use of residual newborn bloodspots in research. [44] In another, race and education were not statistically significantly associated with preferences for de-identification of samples stored in a cancer tissue biobank. [70]

Studies assessing perceptions related to clinical genetics similarly reported more privacy-related concern among Non-White participants. Latinas in one study were most likely to agree that genetic testing results would not stay confidential. [73] African-American and Latina participants were also more likely to worry that genetic testing results would be used to show that their ethnic group is not as “good” as others (p < 0.03). African-Americans had the highest level of medical mistrust on a 60-point scale (mean of 29.2 vs. 27.3 for Latinas and 19.4 for Caucasians, significantly higher in African-Americans and Latinas vs. Whites, p ≤ 0.0001). In one study, African-Americans and Hispanics were less likely to say they would participate in pharmacogenomic testing than Whites or Asians (p < 0.05). [72] Conversely, if disclosure of pharmacogenomic testing results to employers were to occur, African-Americans (Odds Ratio (OR) = 1.88, p ≤ 0.01), Asians (OR = 2.6, p ≤ 0.001), and Hispanics (OR = 3.1, p ≤ 0.001) were more likely than Whites to participate in genetic testing. [72]
Age. Several studies also addressed the effects of age on differences in perceptions, with older people typically endorsing fewer privacy-related concerns. In one study, younger veterans and those serving in or since the Vietnam War considered privacy important in the design of a biobank. [29] In another study, older participants were not as likely as younger ones to feel that personal identification from shared data was an imminent risk. [38, 47, 48] In a third study, older individuals participating in a study of dementia risk had less concern about sharing their genetic data in publicly accessible databases, although most participants, regardless of age, felt that data sharing benefits outweighed the risks. [52] In a study of pharmacogenomics testing, individuals over age 50 expressed less concern about anonymity than younger individuals. [72] Another study noted that younger people were more likely to want notification about the use of newborn blood spots for research. [44] Older people were not, however, completely sanguine about this type of research. In a final study, older respondents were more likely to endorse the removal of identifiers if samples were to be used in future research (p = 0.009). [70]

Sex. The influence of a respondent’s sex on privacy opinions was not demonstrated consistently. In one study, female sex was associated with allowing use of residual newborn bloodspots in research, [44] while in another, women were more likely than men to find narrow consent for biobank research acceptable (p ≤ 0.01). [27] A third study reported few differences between male and female willingness to participate in pharmacogenomics research, [72] and while another reported little difference in the level of privacy concern among male and female respondents to questions about participating in psychiatry-related genetic research. [49]

Status as a parent. The demonstration of parental views on genetic privacy has similarly been mixed. In one study, the parents of pediatric patients selected more restrictive data sharing options than older participants (OR for selecting no release: 6.88, 95% Confidence Interval (CI): 2.19 to 21.61). [38, 47, 48] More parents than other adults felt it was extremely important to be involved with data sharing decisions (OR = 4.11; 95% CI: 1.67–10.12, p ≤ 0.006). By contrast, in a different study, parents with a higher education level, youngest child with multiple health conditions, or those planning to have a child in 5 years were more interested in newborn WGS, even when future use of the data was a possibility (OR = 1.81–1.95, p ≤ 0.05). [66] In another study, significantly more individuals without living children noted that they were very concerned about privacy than those with children (29% vs. 25%, p ≤ 0.04). [49]

Education and socioeconomic factors. Privacy concerns were not consistently associated with either higher or lower levels of education or income. In a large survey (n = 13,000), individuals with higher education were more likely to express willingness to provide broad consent for data sharing. [12] In one biobanking study, respondents with a higher education level and those with a higher household income were more likely to consider privacy important. [29] Similarly, individuals with higher education and income levels were more willing to participate in pharmacogenomic testing if data collected were “anonymous” and not disclosed to employers or insurers. [72] In another study of African-Americans’ willingness to enroll in a cancer genetics registry, higher education was associated with enrollment, while lower education was associated with lower trust. [65] In one survey of 1,243 participants in the US Bipolar Genome Study assessing psychiatric genetic research, 410 individuals (33%) of people with a disability, 336 individuals (27%) of those who were unemployed, and 224 individuals (18%) of respondents in managerial positions were very concerned about privacy (p ≤ 0.02). [49]

Other modifiers of perceptions. The studies addressed a number of other factors that modified attitudes toward privacy. In one large survey, people who were more religious were less likely to support broad consent for data sharing. [12] Another study reported that participants with “conservative political views” were less likely to endorse WGS than those identifying as politically moderate (OR = 0.64, p ≤ 0.05). [66] In a study of African-Americans’
opinions about a cancer genetics registry, less satisfaction with one’s cancer care and an individualistic versus collectivist (family) orientation were associated with lower trust ($p \leq 0.02$). [65] Cancer patients in a different study categorized as having a high conversation orientation, in which the family climate encourages free interaction (as opposed to a conformity orientation, in which family climate stresses homogeneity of attitudes and beliefs) had more permeable family and privacy boundaries and were more likely to communicate about genetic cancer risk with family members. [37]

**Views of professionals**

Fewer studies explored the views of professionals. Some studies included mixed stakeholder groups or non-patient/public stakeholders. In one study in which IRB professionals, researchers, and participants were asked to identify which statements were most important to include in consent forms, the opinions varied widely. The statement that “there is a risk that someone could get access to data we have stored about you,” as well as three statements about privacy protections were deemed important more often by researchers and IRBs than by research participants. [50]

IRB professionals generally were more likely than investigators to worry that research participants would be identified and come to harm. In a study comparing views of genetics researchers and IRB personnel, more researchers than IRB personnel felt that personal identification was unlikely to result from a study involving coded genetic data (70% vs. 52%). [46, 60, 77] Similarly, few researchers felt harm was likely to result from identification (11%) compared with 37% of IRB professionals.

In a twenty-year-old study assessing the views of journal editors and genetic researchers, of the 177 researchers surveyed, 90 individuals (51%) had confidentiality concerns about publishing genetic pedigrees. [75] Four of the 14 (29%) editors surveyed noted that they had been contacted by a research participant about perceived breaches of privacy or confidentiality, while eight had confidentiality concerns about publishing pedigrees (while two had no concerns and four were not certain).

**Discussion**

Making genomic and affiliated data available for research is a critical goal for various policies in the United States, one that many people endorse. [13] The NIH, under its Genome Data Sharing Policy, requires its investigators to get broad consent for data sharing as a condition of funding for genome-wide research and mandates that identifiers be removed from data prior to being shared or deposited into databases for use by other investigators. [9] Current laws, such as the Health Insurance Portability and Accountability Act (HIPAA), [84] permit the sharing of patient information, at times in identifiable form, without permission of the individuals to whom the data corresponds, in a variety of circumstances including for some forms of research. [85] The U.S. Common Rule also permits the use of de-identified data without consent and with limited to no IRB oversight and endorses an expansive role for broad consent of identified data. [86] Yet policies and laws must ensure that adequate attention be paid to the concerns, many of which fall under the broad term “genetic privacy,” of those from whom data are obtained to sustain public support for genomic research. A critical step, then, is to ascertain what apprehensions people have about genetic privacy and the use of data about them.

The picture of genetic privacy that emerges from this systematic literature review is complex and riddled with gaps. When asked specifically “are you worried about genetic privacy,” the general public, patients, and professionals frequently agreed. In many cases, however, that question was posed poorly or only in the most general terms, leaving the reader and policy
makers with little idea of what specific issue or issues actually concerned respondents. In the future, investigators need to specify which particular aspects of genetic privacy they are interested in. Since decisions about genetic testing and data are not made in a vacuum, it is critical to ask respondents about what trade-offs they are willing to make and risks they are willing to accept for their own health, for advancing science, and for their interest and convenience.

A number of the studies we examined did provide some insight into what worries people have. Many participants expressed concern that genomic and medical information would be revealed to others. Yet rather than parsing out how participants thought these revelations might occur, investigators and respondents frequently seemed to conflate privacy, confidentiality, control, and security. [78] Although the term confidentiality was used quite frequently, none of the studies explored participants’ beliefs about whether clinicians would breach such an obligation. This was true even for the few studies that focused on patients’ expectations and concerns about clinical genetic testing.[36, 42, 63, 69] Understanding what patients think clinicians will do with genomic data warrants more attention for a number of reasons. The first is the ongoing debate about whether physicians should warn at-risk relatives— even over the initial patient’s objections— of genetic findings that have implications also for them. [87, 88] More generally, worries that identified genomic information may be revealed in the setting of clinical care may have some merit since genomic information— some of which comes from return of research results— is increasingly incorporated into electronic medical records, where many security breaches have transpired. [89] Little research has been done, moreover, to understand what people think about the revelations inherent in the personal health information that they are often compelled to provide [90] or the impact of their participation or that of their relatives in direct-to-consumer testing on the availability of data that also have implications about their health. [91, 92] Interestingly, at least some who place their personally identified information in open access databases nonetheless expect their privacy to be protected. [18]

By contrast, despite references by the NIH [93] and in the proposed changes to the Common Rule [94, 95] to the case of Henrietta Lacks, whose cervical cancer cells were used to create a widely used cell line, [96] to the best of our knowledge, there have been almost no reports of breaches of research data and few reports of deliberate efforts to identify research participants except those undertaken for demonstration. [97–99] Still, it is important to understand the types of data-driven attacks that individuals could perpetrate against genomic data. First, it has been demonstrated that less than one hundred genomic variants, in the form of single nucleotide polymorphisms, are sufficient to represent an individual uniquely. [100] Thus, when someone has an identified genomic record, then matching it to a de-identified record with the same variants would be relatively trivial. It has further been shown that a de-identified genomic record can be linked back to an individual’s identity through inference strategies. For instance, Gymrek and colleagues showed that patterns of short tandem repeats (STRs) on the Y-chromosome could be used to infer the surname for the corresponding individual through online websites where <surname, STR> information are reported. [98] And in the event that additional demographics are available on the corresponding person (e.g., geographic information in the form of U.S. State of residence and age), the record could be uniquely linked to data on named individuals gathered from information brokers.

While these identifications were committed against individual-level genomic records, it has also been shown that an individual’s presence can be detected in summary genomic data from genome-phenome association studies. This was initially demonstrated by Homer and colleagues, where they showed that, if a named genomic record was in hand, then the similarity of that record could be compared to the aggregate statistics from a study and some reference population, such as 1000 Genomes. [97] This attack required on the order of 10,000 genomic variants, but it this type of “presence” attack has been subsequently been refined over the years to
require less genomic information [101] and adapted to penetrate the Beacon system of the Global Alliance for Genomics and Health. [102] Yet it has also been shown that such attacks may make overly strong assumptions about the prior probability that a targeted individual could be in the study to begin with, which suggests that the chance of a privacy violation is much lower than was previously thought. [103] This concept was formalized in a game theoretic framing of the problem, where it was shown that the amount of effort and expense necessary to perpetrate an attack may be greater than the actual value one reaps from doing so, [104] suggesting that while attacks on genomic data are possible, individuals and entities in the private sector may not be likely to attempt them.

Nonetheless, there has been much debate about the risk that a person could be re-identified from their de-identified DNA or genetic data and many calls for more robust protection. [105–108] The identifiability issue, for example, animated recent proposals to designate biospecimens and data derived from them as identifiable per se for purposes of human research regulation. [94, 95] In 2015 the Working Group of the Precision Medicine Initiative went further and recommended the creation of additional safeguards for data and legal penalties for inappropriate re-identification. [109] Under the authority of the 21st Century Cures Act, the NIH now automatically issues Certificates of Confidentiality to all federally-funded research involving biospecimens and individual genomic data. [110] Yet one of the main reasons the drafters of the proposed changes to the Common Rule cited for not defining biospecimens as identifiable, which would have required almost universal consent, was that researchers and particularly the public worried that such a provision “could significantly harm the ability to do important research without producing any substantial off-setting benefits.” [111] Even more telling, when explicitly asked, people frequently opined that they were willing to pursue genetic testing in the clinic or in research even with some risk to their privacy.

Some investigators, as part of their exploration of privacy, explicitly asked how much control people wanted to have over the use of the genomic data they had provided. The responses varied widely from participants’ being happy to cede control to others to their wanting the ability to decide about all future uses. This range was similar to those seen in examinations of individuals’ opinions about data sharing more broadly, which often varied depending on context, such that parents were often more willing to share data about themselves than that of their children. [12, 13]

Many of the studies we examined focused largely on assessing individuals’ worries that they could be harmed if genetic information were divulged. In particular, concern about adverse use by employers and insurers loomed large, both for investigators and the public, especially taking into account the 149 papers that were excluded from this analysis because they focused solely on discrimination. Given the amount of attention devoted to eliciting respondents’ worries about being harmed by how others use genetic data, it is noteworthy that of the studies we examined, few studies explored patients’ and the public’s opinions about the efficacy of legal protections against discrimination in employment and access to health insurance and of privacy more generally. The few that did focused on GINA, which limits how genetic information can be accessed and used. Some respondents found this law reassuring, although others noted the strong criticisms that have been leveled against it for its lack of efficacy. [112, 113] The potential value of other pertinent laws, such as HIPAA, the Americans with Disabilities Act, and those that eliminate the exclusion of pre-existing conditions from coverage in health insurance, was not explored at all—even though all of them offer some degree of protection against discrimination on the basis of genetic information. [114] Ultimately, moreover, there is little evidence that employers and insurers actually engage in discrimination on the basis of genetic information. [22] More generally, none of the studies we examined explored whether participants felt that they were protected by common law privacy claims or state privacy laws.
While we recognize that investigators are limited in the number of topics they explore, it is nonetheless striking how little is known about people’s opinions about how well the law protects them and information derived from them. Although legal scholars and advocates have devoted much attention to these strengths and weaknesses of these legal protections,[115, 116] it would be helpful to know more about how much these laws matter to patients and research participants, particularly as they make decisions about clinical testing and research participation.

Participants frequently expressed concerns about how the government might use data about them. These individuals tended to fall into two main groups. Many opined that government databanks simply would not provide adequate security for these data so that information about the participants would end up in the wrong hands. Others expressed concern that law enforcement would access these data, often for criminal investigations, particularly if the data were already held by the government. These studies, of course, were conducted prior to the use of information contained in GEDMatch, a genealogy database, to identify the Golden State Killer,[117] which has spurred a new debate about whether it is appropriate for the government to use such data to identify potential perpetrators.[118] Interestingly, genomic data collected in federally funded research is particularly protected from such uses since “identifiable, sensitive information,” which was defined by the NIH in its recent guidance on Certificates of Confidentiality as including “[r]esearch that involves the generation of individual level, human genomic data from biospecimens, or the use of such data,”[110] is “immune from the legal process, and shall not, without the consent of the individual to whom the information pertains, be admissible as evidence or used for any purpose in any action, suit, or other judicial, legislative, or administrative proceeding.”[119]

The research conducted to date indeed sheds some light on which people are more likely than others to have concerns about privacy. This is important because there is much reason to pursue the involvement of all people in genomics research in order to discover the impact of genomic variation on disease and health and to be concerned about the availability of genomic medicine for underrepresented populations due to inadequate inclusion in research. [120] Thus, the fact that more racial and ethnic minorities in many studies express concerns about the privacy of their genetic information and reluctance to take part in research than do Whites makes the challenges of addressing the trepidations of minority populations clear. At the same time, it is also important that some people have reservations about genomic information among all demographics studied.

Much remains to be learned about the factors that form people’s beliefs about genetic privacy, including their family and community networks, in person and virtual, as well as media, TV, film, and popular culture. [121, 122] We believe it is important for future studies to conduct investigations at greater depth into which concerns about genetic privacy are most salient to people, the social forces that influence those perceptions, and the contexts that affect their decision making. It is further critical to identify the social practices that will make the collection and use of these data more trustworthy for participants and patients, as well as to identify the circumstances that lead people to set aside worries and decide to participate in research. Even though not all people will seek or endorse the collection and use of genomic data, a more holistic understanding of the social practices and structures in which these data are obtained can enable individuals, groups, and policy makers to make more informed choices in the future.

It is nonetheless possible, based on our analysis of existing data, to make some observations and recommendations about current consent practices. The new provisions for broad consent for use of identifiable private information or identifiable biospecimens do require the disclosure of information about who may have access to data about research participants. [123] More, however, needs to be disclosed about the likelihood that an individual could be
harmed by third parties depending on who is using the data. In particular, access by non-
researchers to de-identified data used in federally-funded research is actually quite limited
legally and practically. By contrast, returning personal research results to participants, espe-
cially if those data are placed in their medical records or posted to open access websites, opens
these individuals up to greater risk, both because such results are more accessible to others and
because the law’s protection against adverse use once data are available is incomplete.

Materials and methods

Information sources and eligibility criteria
To perform this review, we searched multiple databases across various disciplines, including
the MEDLINE database via PubMed, Web of Knowledge (Science Citation Index and Social
Sciences Index), Applied Social Sciences Index, PsycInfo, ACM Digital Library, IEEE Explore,
and Sociological Abstracts from January 1990 to November 2016. We applied a combination
of controlled vocabulary and key terms related to genetics, privacy, genetic research, DNA
databases, and perception (e.g., “privacy”, “confidentiality”, “genomics”, and “opinion”). In
addition, we hand-searched the reference lists of included articles and recent reviews [13, 124–
129] addressing privacy and genetic information to identify additional potentially relevant
articles. This hand-searching process continued until July 2017. The complete set of search
strategies is available in S3 Table.

We developed inclusion criteria collaboratively, including empirical studies of any design
that contained primary data about individuals’ opinions or perceptions related to real or hypo-
thetical privacy issues associated with human genetic information in clinical care and research.
We limited inclusion to English language studies conducted solely with U.S. populations. We
used a semi-automated screening process to conduct an initial screen of the titles of abstracts
of studies to eliminate non-empirical research. The screening algorithm was architected to
search for investigations where 1) the country in which a study was run (to triage studies out-
side of the United States), 2) the focus was solely on non-human genetics (e.g., genetically
modified crops and animals), and 3) no empirical results were generated. We further searched
the titles, abstracts, and indexing terms and controlled vocabulary of the group of “non-empir-
ical” studies culled by the algorithm for the use of salient keywords, such as privacy or confi-
dentiality. In this latter case, we retained these studies for manual screening as described
below. Two investigators (EC, BM) independently screened 2,335 studies classified as an
empirical investigation for inclusion, with disagreements resolved through discussion to reach
consensus. We excluded 149 articles that addressed only views about genetic discrimination
since that topic was not the primary focus of this review. Ultimately, 53 studies were included
for further analysis.

Assessment of study quality
Four investigators (EC, CH, BM, NS) independently evaluated the methodologic quality of
studies using prespecified questions employed in a prior systematic review of informed con-
sent for biobanking. [13] Two reviewers (EC, NS) resolved discrepancies in quality
assessment.

Data extraction and analysis
One team member (NS) initially extracted the study design, study population characteristics
(e.g., age, sex, and stakeholder type), methodologic characteristics (study design), and baseline
and outcome data on constructs of interest (privacy-related perceptions) from eligible studies.
Characteristics of studies identified later were extracted by three other team members (EC, CH, SS). The findings were too heterogeneous to permit a meaningful quantitative analysis.

**Categorizing aspects of privacy explored in these studies**

Three investigators (EC, CH, SS) analyzed each study in order to determine which aspects of privacy the investigators explored and, in the case of qualitative studies, which topics participants raised. These team members developed categories for these aspects of privacy through an iterative process informed by categories raised in earlier literature, illustrated in Fig 1. The first set of topics—whether data or identity are known, which often elicits dignitary concerns—was subdivided into concerns about 1) identifiability, 2) confidentiality, and 3) other issues, such as self-identity. We grouped articles addressing informed consent and the desire for personal control to protect privacy with the value of institutional practices and laws in providing protection into the domain of control. The next domain—data users—addressed the various entities who potentially could use data, which included researchers, academic institutions, commercial entities, government agencies, and foreign users. For each entity in this group, we examined responses regarding fears and risks, on the one hand, and trust, on the other. Finally, we ascertained whether investigators explored participants’ views about their willingness to trade their own privacy for some service or good, such as advances in science. Two team members (EC, CH) then labeled each study with these categories. Some of the individual studies addressed more than one aspect of privacy. Disagreements were resolved through debate to reach consensus.

**Supporting information**

S1 Table. List of studies included in the systematic literature review with first author, year of publication, population studies, research method(s), number of participants, and categories of concerns regarding genetic privacy assessed. (DOCX)

S2 Table. Main data extraction files. (XLSX)

S3 Table. GetPreCiSe search strategy. (PDF)

**Acknowledgments**

The authors wish to thank the faculty, students, and staff of the Center for Genetic Privacy and Identity in Community Settings (GetPreCiSe) for their helpful comments, criticisms, and discussion during the development of this manuscript. We would also like to thank Melissa McPheeters, Jessica Kimber, and Shannon Potter for their assistance with setting up and conducting the systematic literature review, and Samantha C. Smith for her expert research assistance in extracting data.

**Author Contributions**

**Conceptualization:** Ellen W. Clayton, Colin M. Halverson, Bradley A. Malin.

**Data curation:** Ellen W. Clayton, Colin M. Halverson, Nila A. Sathe, Bradley A. Malin.

**Formal analysis:** Ellen W. Clayton, Colin M. Halverson, Nila A. Sathe, Bradley A. Malin.

**Funding acquisition:** Ellen W. Clayton, Bradley A. Malin.
Investigation: Ellen W. Clayton, Colin M. Halverson, Nila A. Sathe, Bradley A. Malin.

Methodology: Nila A. Sathe.

Project administration: Nila A. Sathe.

Software: Bradley A. Malin.

Validation: Nila A. Sathe, Bradley A. Malin.

Writing – original draft: Ellen W. Clayton.

Writing – review & editing: Colin M. Halverson, Nila A. Sathe, Bradley A. Malin.

References

1. Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, Lyke KJ, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014; 89(1):25–33. https://doi.org/10.1016/j.mayocp.2013.10.021 PMID: 24388019

2. Ramos EM, Din-Lovinescu C, Berg JS, Brooks LD, Duncanson A, Dunn M, et al. Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet. 2014; 166C(1):93–104. https://doi.org/10.1002/ajmg.c.31386 PMID: 24634402

3. Goldspiel BR, Flegel WA, DiPatrizio G, Sissung T, Adams SD, Penzak SR, et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc. 2014; 21(3):522–8. https://doi.org/10.1136/amiajnl-2013-001873 PMID: 24302286

4. Ramos EM, Din-Lovinescu C, Berg JS, Brooks LD, Duncanson A, Dunn M, et al. Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet. 2014; 166C(1):93–104. https://doi.org/10.1002/ajmg.c.31386 PMID: 24634402

5. Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res. 2013; 19(7):1894–901. https://doi.org/10.1158/1078-0432.CCR-12-1894 PMID: 23344264

6. National Institutes of Health. Undiagnosed Diseases Network 2017 [cited 2017 10/1/2017]. Available from: https://undiagnosed.hms.harvard.edu/.

7. Bloss CS, Zeeland AA, Topol SE, Darst BF, Boeldt DL, Erikson GA, et al. A genome sequencing program for novel undiagnosed diseases. Genet Med. 2015; 17(12):995–1001. https://doi.org/10.1038/gim.2015.21 PMID: 25790160

8. Bastarache L, Hughey JJ, Hebbring S, Marlo J, Zhao W, Ho WT, et al. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science. 2018; 359(6381):1233. https://doi.org/10.1126/science.aai4043 PMID: 29590070

9. National Institutes of Health. NIH Genomic Data Sharing 2017 [10/16/2017]. Available from: https://osp.od.nih.gov/scientific-sharing/genomic-data-sharing/.

10. Department of Homeland Security. DoD Policy for the Protection of Human Subjects, Final Rule. Federal Register2017. p. 7149–274.

11. 21st Century Cures Act, Pub. L. No. 114-255(2016).

12. Sanderson SC, Brothers KB, Mercaldo ND, Clayton EW, Antommaria AHM, Auffoa SA, et al. Public Attitudes toward Consent and Data Sharing in Biobank Research: A Large Multi-Site Experimental Survey in the US. American journal of human genetics. 2017; 100(3):414–27. https://doi.org/10.1016/j.ajhg.2017.01.021 PMID: 28190457

13. Garrison NA, Sathe NA, Antommaria AH, Holm IA, Sanderson SC, Smith ME, et al. A systematic literature review of individuals’ perspectives on broad consent and data sharing in the United States. Genetics in medicine: official journal of the American College of Medical Genetics. 2015.

14. Solove DJ. A taxonomy of privacy. U Pa L Rev. 2005; 154:477.

15. Warren S, Brandeis L. The Right to Privacy. Harvard Law Review. 1890; 4.

16. Hull SC, Sharp RR, Botkin JR, Brown M, Hughes M, Sugarman J, et al. Patients’ views on identifiability of samples and informed consent for genetic research. The American journal of bioethics: AJOB. 2008; 8(10):62–70. https://doi.org/10.1080/15265160802478404 PMID: 19003716
17. AMA Council on Ethical and Judicial Affairs. https://www.ama-assn.org/delivering-care/ama-code-medical-ethics: American Medical Association; 2016.

18. Haeusermann T, Greshake B, Blasimme A, Irdam D, Richards M, Vayena E. Open sharing of genomic data: Who does it and why? PloS One. 2017; 12(5):e0177158. https://doi.org/10.1371/journal.pone.0177158 PMID: 28486511

19. Scott DM, Nwulia E, Kwagyan J, Cain G, Marshall VJ, Kalu N, et al. Genetic testing for the susceptibility to alcohol dependence: interest and concerns in an African American population. Genetic testing and molecular biomarkers. 2014; 18(8):538–45. https://doi.org/10.1089/gtmb.2013.0417 PMID: 24926856

20. Mello MM, Wolf LE. The Havasupai Indian tribe case—lessons for research involving stored biologic samples. New England Journal of Medicine. 2010; 363(3):204–7. https://doi.org/10.1056/NEJMp1005203 PMID: 20538622

21. McEwen JE, Boyer JT, Sun KY, Rothenberg KH, Lockhart NC, Guyer MS. The Ethical, Legal, and Social Implications Program of the National Human Genome Research Institute: reflections on an ongoing experiment. Annu Rev Genomics Hum Genet. 2014; 15:481–505. https://doi.org/10.1146/annurev-genom-090413-025327 PMID: 24773317

22. Green RC, Lautenbach D, McGuire AL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015; 372(5):397 –9. https://doi.org/10.1056/NEJMp1404776 PMID: 25629736

23. El Emam K, Jonker E, Arbuckle L, Malin B. A systematic review of re-identification attacks on health data. PLoS One. 2011; 6(12):e28071. Epub 2011/12/14. https://doi.org/10.1371/journal.pone.0028071 PMID: 22164229

24. Joly Y, Feze IN, Song L, Knoppers BM. Comparative Approaches to Genetic Discrimination: Chasing Shadows? Trends in Genetics. 2017.

25. Wauters A, Van Hoyweghen I. Global trends on fears and concerns of genetic discrimination: a systematic literature review. Journal of human genetics. 2016; 61(4):275–82. https://doi.org/10.1038/jhg.2015.151 PMID: 26740237

26. Kimball BC, Nowakowski KE, Maschke KJ, McCormick JB. Genomic data in the electronic medical record: perspectives from a biobank community advisory board. J Empir Res Hum Res Ethics. 2014; 9(5):16–24. https://doi.org/10.1177/1556264614553922 PMID: 25747687

27. Ewing AT, Erby LAH, Bollinger J, Tetteyfio E, Ricks-Santi LJ, Kaufman D. Demographic Differences in Willingness to Provide Broad and Narrow Consent for Biobank Research. Biopreservation and Biobanking. 2015; 13(2):98–106. https://doi.org/10.1089/bio.2014.0032 PMID: 25825819

28. Kaufman D, Murphy J, Erby L, Hudson K, Scott J. Veterans’ attitudes regarding a database for genomic research. Genet Med. 2009; 11(5):329–37. https://doi.org/10.1097/GIM.0b013e31819994f8 PMID: 19346960

29. Friedman BD, Bolic-Jankovic D, Kennedy CR, LeBlanc J, Eastman A, Barillas J, et al. Perspectives of Decisional Surrogates and Patients Regarding Critical Illness Genetic Research. AJOB empirical bioethics. 2016; 7(1):39–47. https://doi.org/10.1080/23294515.2015.1039148 PMID: 26752784

30. Majumder MA, Cook-Deegan R, McGuire AL. Beyond Our Borders? Public Resistance to Global Genomic Data Sharing. PLoS Biol. 2016; 14(11):e200206. https://doi.org/10.1371/journal.pbio.200206 PMID: 27806054

31. Sanderson SC, Linderman MD, Suckiel SA, Diaz GA, Zinberg RE, Ferryman K, et al. Motivations, concerns and preferences of personal genome sequencing research participants: Baseline findings from the HealthSeq project. European Journal of Human Genetics. 2016; 24(1):14–20. https://doi.org/10.1038/ejhg.2015.118 PMID: 26036856

32. Weidman, J, Aurite, W, Grossklags, J, editor. Understanding Interdependent Privacy Concerns and Likely Use Factors for Genetic Testing: A Vignette Study. 3rd International Workshop on Genome Privacy and Security (GenoPi’16); 2016; Chicago, IL.
36. Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, et al. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer. 2016; 122(10):1588–97. https://doi.org/10.1002/cncr.29951 PMID: 26970385

37. Rauscher EA, Hesse C, Miller S, Ford W, Youngs EL. Privacy and Family Communication about Genetic Cancer Risk: Investigating Factors Promoting Women’s Disclosure Decisions. Journal of Family Communication. 2015; 15(4):368–86.

38. Burstein MD, Robinson JO, Hilsenbeck SG, McGuire AL, Lau CC. Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014; 133(4):690–7. https://doi.org/10.1542/peds.2013-1592 PMID: 24616359

39. Nagaraj CB, Rothwell E, Hart K, Latimer S, Schiffman JD, Botkin JR. Attitudes of parents of children with serious health conditions regarding residual bloodspot use. Public Health Genomics. 2014; 17(3):141–8. https://doi.org/10.1159/000360251 PMID: 24713606

40. Platt J, Bollinger J, Dvoskin R, Kardia SL, Kaufman D. Public preferences regarding informed consent models for participation in population-based genomic research. Genet Med. 2014; 16(1):11–8. https://doi.org/10.1038/gim.2013.59 PMID: 23660530

41. Quinn GP, Koskan A, Sehovic I, Pal T, Meade C, Gwede CK. Contrasting the ethical perspectives of biospecimen research among individuals with familial risk for hereditary cancer and biomedical researchers: implications for researcher training. Genetic testing and molecular biomarkers. 2014; 18(7):467–73. https://doi.org/10.1089/gtbm.2013.0461 PMID: 24786355

42. Rogith D, Yusuf RA, Hovick SR, Peterson SK, Burton-Chase AM, Li Y, et al. Attitudes regarding privacy of genomic information in personalized cancer therapy. J Am Med Inform Assoc. 2014; 21(2):e320–5. https://doi.org/10.1136/amiajnl-2013-002579 PMID: 24737606

43. Thiel DB PT, Platt J, King SB, Kardia SL. Community perspectives on public health biobanking: an analysis of community meetings on the Michigan BioTrust for Health. J Community Genet. 2014; 5(2):125–38. https://doi.org/10.1007/s12687-013-0162-0 PMID: 23893769

44. Botkin JR, Rothwell E, Anderson R, Stark L, Goldenberg A, Lewis M, et al. Public attitudes regarding the use of residual newborn screening specimens for research. Pediatrics. 2012; 129(2):231–8. https://doi.org/10.1542/peds.2011-0970 PMID: 22250018

45. Duquette D, Langbo C, Bach J, Kley M. Michigan BioTrust for Health: Public Support for Using Residual Dried Blood Spot Samples for Health Research. Public Health Genomics. 2012; 15(3–4):146–55. https://doi.org/10.1159/000334656 PMID: 22486457

46. Edwards KL, Lemkne AA, Trinidad SB, Lewis SM, Starks H, Snapinn KW, et al. Genetics researchers’ and IRB professionals’ attitudes toward genetic research review: a comparative analysis. Genetics in medicine: official journal of the American College of Medical Genetics. 2012; 14(2):236–42.

47. Oliver JM, Slashinski MJ, Wang T, Kelly PA, Hilsenbeck SG, McGuire AL. Balancing the risks and benefits of genomic data sharing: genome research participants’ perspectives. Public Health Genomics. 2012; 15(2):106–14. https://doi.org/10.1159/000334718 PMID: 22213783

48. McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, et al. To share or not to share: a randomized trial of consent for data sharing in genome research. Genetic testing and molecular biomarkers. 2012; 15(2):467–73. https://doi.org/10.1089/gtbm.2013.0461 PMID: 24786355

49. Nwulia EA, Hipolito MM, Aamir S, Lawson WB, Nurnberger JI Jr., Bi GSC. Ethnic disparities in the perceptions of ethical risks from psychiatric genetic studies. Am J Med Genet B Neuropsychiatr Genet. 2011; 156B(5):569–80. https://doi.org/10.1002/ajmg.b.31198 PMID: 21595007

50. Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. Simplifying informed consent for biorepositories: stakeholder perspectives. Genetics in medicine: official journal of the American College of Medical Genetics. 2010; 12(9):567–72.

51. Lemke AA, Wolf WA, Hebert-Beirne J, Smith ME. Public and biobank participant attitudes toward genetic research participation and data sharing. Public Health Genomics. 2010; 13(6):368–77. https://doi.org/10.1159/000276767 PMID: 20805700

52. Trinidad SB, Fullerton SM, Bares JM, Jarvik GP, Larson EB, Burke W. Genomic research and wide data sharing: Views of prospective participants. Genet Med. 2010; 12(8):486–95. https://doi.org/10.1097/GIM.0b013e3181e38f9e PMID: 20535021

53. Goldenberg AJ, Hull SC, Botkin JR, Wilfond BS. Pediatric Biobanks: Approaching Informed Consent for Continuing Research After Children Grow Up. J Pediatr. 2009; 155(4):578–83. https://doi.org/10.1016/j.peds.2009.04.034 PMID: 19595370

54. Ormond KE, Cirino AL, Helenowski IB, Chisholm RL, Wolf WA. Assessing the understanding of biobank participants. American journal of medical genetics Part A. 2009; 149a(2):188–98. https://doi.org/10.1002/ajmg.a.32635 PMID: 19161150
55. McGuire AL, Fisher R, Cusenza P, Hudson K, Rothstein MA, McGraw D, et al. Confidentiality, privacy, and security of genetic and genomic test information in electronic health records: points to consider. Genetics in medicine: official journal of the American College of Medical Genetics. 2008; 10(7):495–9.

56. Goddard KA, Smith KS, Chen C, McMullen C, Johnson C. Biobank Recruitment: Motivations for Non-participation. Biopreserv Biobank. 2009; 7(2):119–21. https://doi.org/10.1089/bio.2009.0006 PMID: 22087353

57. Leiman DA, Lorenzi N, Wyatt J, Doney AS, Rosenbloom T. US and Scottish Health Professionals attitudes toward DNA biobanking. AMIA Annual Symposium proceedings / AMIA Symposium AMIA Symposium. 2007:1027. E PubMed PMID: 18694125; PubMed Central PMCID: PMCINCLUDE.

58. Freeman BD, Kennedy CR, Coopersmith CM, Zehnbauer BA, Buchman TG. Genetic research and testing in critical care: surrogates’ perspective. Critical care medicine. 2006; 34(4):986–94. https://doi.org/10.1097/01.CCM.0000206113.47535.2A PMID: 16484903; PubMed Central PMCID: PMCINCLUDE.

59. Bevan JL, Lynch JA, Dubrinya TN, Harris TM, Achter PJ, Reeder AL, et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med. 2003; 5(5):393–9. PubMed PMID: WOS:000187774700008; PubMed Central PMCID: PMC1450183.

60. Edwards KL, Lemke AA, Trinidad SB, Lewis SM, Starks H, Quinn Griffin MT, et al. Attitudes toward Genetic Research Review: Results from a Survey of Human Genetics Researchers. Public Health Genomics. 2011; 14(6):337–45. http://dx.doi.org/10.1159/000324931. PubMed Central PMCID: PMC21487211.

61. Goldenberg AJ, Hull SC, Wilson DS, Sharp RR. Patient Perspectives on Group Benefits and Harms in Genetic Research. Public Health Genomics. 2011; 14(3):135–42. https://doi.org/10.1159/000317497 PubMed PMID: WOS:000290785400003; PubMed Central PMCID: PMCINCLUDE. PMID: 20938159.

62. Cheung C, Buetz MJ, Patrick K, Bresh L. Privacy Attitudes among Early Adopters of Emerging Health Technologies. PLoS One. 2016; 11(11):e0166389. Epub 2016/11/11. https://doi.org/10.1371/journal.pone.0166389 PMID: 27832194; PubMed Central PMCID: PMCINCLUDE.

63. Robinson JO, Carroll TM, Feuerman LZ, Perry DL, Hoffman-Andrews L, Walsh RC, et al. Participants and Study Decliners’ Perspectives About the Risks of Participating in a Clinical Trial of Whole Genome Sequencing. J Empir Res Hum Res Ethics. 2016; 11(1):21–30. Epub 2016/03/02. https://doi.org/10.1177/1556264615624078 PMID: 26928896; PubMed Central PMCID: PMCINCLUDE.

64. Skinner HG, Calancie L, Vu MB, Garcia B, DelMarco M, Patterson C, et al. Using community-based participatory research principles to develop more understandable recruitment and informed consent documents in genomic research. PLoS One. 2015; 10(5):e0125466. Epub 2015/05/06. https://doi.org/10.1371/journal.pone.0125466 PMID: 25938669; PubMed Central PMCID: PMCINCLUDE.

65. Skinner CS, Schildkraut JM, Calingaert B, Hoyo C, Crankshaw SS, Fish L, et al. Factors associated with African Americans’ enrollment in a national cancer genetics registry. Community Genet. 2008; 11(4):224–33. https://doi.org/10.1159/000116883 PMID: 18417970.

66. Goldenberg AJ, Dodson DS, Davis MM, Tarini BA. Parents' interest in whole-genome sequencing of newborns. Genetics in medicine: official journal of the American College of Medical Genetics. 2014; 16(1):78–84. Epub 2013/06/08. https://doi.org/10.1038/gim.2013.76 PMID: 23743552; PubMed Central PMCID: PMCINCLUDE.

67. Bollinger JM, Green RC, Kaufman D. Attitudes about regulation among direct-to-consumer genetic testing customers. Genetic testing and molecular biomarkers. 2013; 17(5):424–8. Epub 2013/04/09. https://doi.org/10.1089/gtmb.2012.0453 PMID: 23560882; PubMed Central PMCID: PMCINCLUDE.

68. Brothers KB, Clayton EW. Parental Perspectives on a Pediatric Human Non-Subjects Biobank. AJOB primary research. 2012; 3(3):21–9. Epub 2012/11/28. https://doi.org/10.1080/21507716.2012.662576 PMID: 23181193; PubMed Central PMCID: PMCINCLUDE.

69. Tabor HK, Stock J, Brazig T, McMullin MJ, Dent KM, Yu JH, et al. Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American journal of medical genetics Part A. 2012; 158a(6):1310–9. Epub 2012/04/26. https://doi.org/10.1002/ajmg.a.35328 PMID: 22532433; PubMed Central PMCID: PMC3426313.

70. Helft PR, Champion VL, Eckles R, Johnson CS, Meslin EM. Cancer patients’ attitudes toward future research uses of stored human biological materials. J Empir Res Hum Res Ethics. 2007; 2(3):15–22. https://doi.org/10.1017/jer.2007.2.3.15 PMID: 19385847.

71. Kaphingst KA, Janoff JM, Harris LN, Emmons KM. Views of female breast cancer patients who donated biologic samples regarding storage and use of samples for genetic research. Clin Genet. 2006; 69(5):393–8. https://doi.org/10.1111/j.1399-0004.2006.00614.x PMID: 16650074.

72. Rothstein MAH, C. A. Public Attitudes about Pharmacogenomics. In: Rothstein MA, editor. Public Attitudes about Pharmacogenomics, in Pharmacogenomics: Social, Ethical, and Clinical Dimensions. 1. Hoboken, NJ: John Wiley & Sons; 2003. p. 3–27.
73. Thompson HS, Valdimarsdottir HB, Jandorf L, Redd W. Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina, and Caucasian women. Patient education and counseling. 2003; 51(3):217–27. Epub 2003/11/25. PMID: 14630378; PubMed Central PMCID: PMC1257493.

74. Tambor ES, Bernhardt BA, Rodgers J, Holtzman NA, Geller G. Mapping the human genome: an assessment of media coverage and public reaction. Genetics in medicine: official journal of the American College of Medical Genetics. 2002; 4(1):31–6. Epub 2002/02/13. PMID: 11839956; PubMed Central PMCID: PMC1205692.

75. Botkin JR, McMahon WM, Smith KR, Nash JE. Privacy and confidentiality in the publication of pedigrees: A survey of investigators and biomedical journals. JAMA: Journal of the American Medical Association. 1998; 279(22):1808–12. http://dx.doi.org/10.1001/jama.279.22.1808 PMID: 9628712

76. Wertz DC. The difficulties of recruiting minorities to studies of ethics and values in genetics. Community Genet. 1998; 1(3):175–9. Epub 2001/10/20. doi: 10.1002/jmg.560010312 PMID: 11657307; PubMed Central PMCID: PMC131092.

77. Lemke AA, Trinidad SB, Edwards KL, Starks H, Wiesner GL. Attitudes toward genetic research review: results from a national survey of professionals involved in human subjects protection. J Empir Res Hum Res Ethics. 2010; 5(1):83–91. https://doi.org/10.1525/jemr.2010.5.1.83 PMID: 20236866; PubMed Central PMCID: PMC2836774.

78. Lemke AA HC, Ross LF. Biobank participation and returning research results: perspectives from a deliberative engagement in South Side Chicago. American journal of medical genetics Part A. 2012; 158A(5):1029–37. https://doi.org/10.1002/ajmg.a.34414 PMID: 22438108

79. Quinn GP KA, Sehovic I, Pal T, Meade C, Gwede CK. Contrasting the ethical perspectives of biospecimen research among individuals with familial risk for hereditary cancer and biomedical researchers: implications for researcher training. Genetic testing and molecular markers. 2014; 18(7):467–73. https://doi.org/10.1089/000016159 PMID: 24786355

80. McGuire AL, Hamilton JA, Lunstroth R, McCullough LB, Goldman A. DNA data sharing: research participants’ perspectives. Genetics in medicine: official journal of the American College of Medical Genetics. 2008; 10(1):46–53. Epub 2008/01/17. https://doi.org/10.1097/GIM.0b013e318191f6e0 PMID: 18197056; PubMed Central PMCID: PMC2767246.

81. Platt J BJ, Dvoskin R, Kaufman D. Public preferences regarding informed consent models for participation in population-based genomic research. Genet Med. 2014; 16(1):11–8. https://doi.org/10.1038/gim.2013.59 PMID: 23660530

82. Genetic Information Nondiscrimination Act, Vol. 42 USC §§ 2000ff et seq. 122 Stat. 881, Stat. 122 Stat. 881 (2008).

83. Health Insurance Portability and Accountability Act, Pub. L. No. Pub. L. 104–191 Stat. 110 Stat. 1936 (1996).

84. US Department of Health and Human Services. Summary of the HIPAA Privacy Rule [cited 2018]. Available from: https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html.

85. Department of Homeland Security, et al. Federal Policy for the Protection of Human Subjects. Federal Register2017. p. 7149–274

86. Hazin R, Brothers KB, Malin BA, Koenig BA, Sanderson SC, Rothstein MA, et al. Ethical, legal, and social implications of incorporating genomic information into electronic health records. Genetics in medicine: official journal of the American College of Medical Genetics. 2013; 15(10):810–6. Epub 2013/08/14. https://doi.org/10.1038/gim.2013.117 PMID: 24030434; PubMed Central PMCID: PMC3926430.

87. Wolf SM, Brannum R, Koenig BA, Petersen GM, Berry SA, Beskow LM, et al. Returning a Research Participant’s Genomic Results to Relatives: Analysis and Recommendations. The Journal of law, medicine & ethics: a journal of the American Society of Law, Medicine & Ethics. 2015; 43(3):440–63. Epub 2015/10/21. https://doi.org/10.1111/jme.12288 PMID: 26479555; PubMed Central PMCID: PMC4617203.

88. Rothstein MA, Taibbott MK. Compelled Disclosures of Health Records: Updated Estimates. J Law Med Ethics. 2017; 45(1):149–55. Epub 2017/07/01. https://doi.org/10.1177/1073110517703109 PMID: 28661287.

89. Phillips AM. Only a click away—DTC genetics for ancestry, health, love, . . . and more: A view of the business and regulatory landscape. Applied & translational genomics. 2016; 8:16–22.
92. Moray N, Pink KE, Borry P, Larmseau MH. Paternity testing under the cloak of recreational genetics. European Journal of Human Genetics. 2017; 25(6):768. https://doi.org/10.1038/ejhg.2017.31 PMID: 28272533

93. Hudson KL, Collins FS. Biospecimen policy: Family matters. Nature. 2013; 500(7461):141–2. https://doi.org/10.1038/500141a PMID: 23925224

94. Department of Health and Human Services. Advance notice of proposed rulemaking, Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators Federal Register2011. p. 44512–31.

95. Department of Homeland Security ea. Notice of Proposed Rule Making, Federal Policy for the Protection of Human Subjects; Federal Register 80: 53933–54061; 2015. p. 53933–4061.

96. Skloot R. The Immortal Life of Henrietta Lacks. New York, New York: Crown Publishing Group; 2010.

97. Home N, Szelinger S, Redman M, Duggan D, Tembe W, Muehling J, et al. Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet. 2008; 4(8):e1000167. Epub 2008/09/05. https://doi.org/10.1371/journal.pgen.1000167 PMID: 18769715; PubMed Central PMCID: PMC2516199.

98. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y. Identifying personal genomes by surname inference. Science. 2013; 339(6117):321–4. Epub 2013/01/19. https://doi.org/10.1126/science.1229566 PMID: 23239047.

99. Raisaro JL, Tramer F, Ji Z, Bu D, Zhao Y, Carey K, et al. Addressing Beacon re-identification attacks: quantification and mitigation of privacy risks. J Am Med Inform Assoc. 2017; 24(4):799–805. Epub 2017/03/25. https://doi.org/10.1093/jamia/ocw167 PMID: 28339683.

100. Lin Z, Owen AB, Altman RB. Genetics. Genomic research and human subject privacy. Science. 2004; 305(5681):183. Epub 2004/07/13. https://doi.org/10.1126/science.1095019 PMID: 15247459.

101. Erlich Y, Narayanian A. Routes for breaching and protecting genetic privacy. Nat Rev Genet. 2014; 15(6):409–21. Epub 2014/05/09. https://doi.org/10.1038/nrg3723 PMID: 24805122; PubMed Central PMCID: PMC4151119.

102. Shringarpure SS, Bustamante CD. Privacy Risks from Genomic Data-Sharing Beacons. American journal of human genetics. 2015; 97(5):631–46. Epub 2015/11/03. https://doi.org/10.1016/j.ajhg.2015.09.010 PMID: 26522470; PubMed Central PMCID: PMC4667107.

103. Craig DW, Goor RM, Wang Z, Paschall J, Ostell J, Feolo M, et al. Assessing and managing risk when sharing aggregate genetic variant data. Nat Rev Genet. 2011; 12(10):730–6. Epub 2011/09/17. https://doi.org/10.1038/nrg3067 PMID: 21921928; PubMed Central PMCID: PMC3349221.

104. Wan Z, Vorobeychik Y, Xia W, Clayton EW, Kantarcioglu M, Malin B. Expanding Access to Large-Scale Genomic Data While Promoting Privacy: A Game Theoretic Approach. American journal of human genetics. 2017; 100(2):316–22. Epub 2017/01/10. https://doi.org/10.1016/j.ajhg.2016.12.002 PMID: 28065469; PubMed Central PMCID: PMC5294764.

105. Lowrance WW. Privacy, Confidentiality, and Identifiability in Genomic Research. NHGRI Workshop; October 3–4, 2006.

106. McGuire AL. Identifiability of DNA data: the need for consistent federal policy. Am J Bioeth. 2008; 8(10):75–6. https://doi.org/10.1080/15265160802478511 PMID: 19003718.

107. Gutmann A, Wagner JW. Found your DNA on the web: Reconciling privacy and progress. Hastings Center Report. 2013; 43(3):15–8. https://doi.org/10.1002/hast.162 PMID: 23650663.

108. Rodriguez LL, Brooks LD, Greenberg JH, Green ED. The complexities of genomic identifiability. Science. 2013; 339(6117):275–6. https://doi.org/10.1126/science.1234992 PMID: 23329035.

109. Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director N. The Precision Medicine Initiative Cohort Program–Building a Research Foundation for 21st Century Medicine. 2015.

110. National Institutes of Health. Notice of Changes to NIH Policy for Issuing Certificates of Confidentiality 2017 [cited 2018 6/30/2018]. Available from: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html.

111. Menikoff J, Kaneshiro J, Pritchard I. The Common Rule, Updated. N Engl J Med. 2017; 376(7):613–5. Epub 2017/01/20. https://doi.org/10.1056/NEJMp1700736 PMID: 28130146.

112. Green RC, Lautenbach D, McGuire AL. GINA, Genetic Discrimination, and Genomic Medicine. New England Journal of Medicine. 2015; 372(5):397–9. https://doi.org/10.1056/NEJMp1404776 PMID: 25629736.

113. Roberts JL. Preempting discrimination: Lessons from the genetic information nondiscrimination act. Vand L Rev. 2010; 63:437.
114. Clayton EW. Why the Americans with Disabilities Act Matters for genetics. JAMA. 2015; 313(22):2225–6. https://doi.org/10.1001/jama.2015.3419 PMID: 26057280.

115. Dressler LG, Terry SF. How will GINA influence participation in pharmacogenomics research and clinical testing? Clin Pharmacol Ther. 2009; 86(5):472–5. Epub 2009/10/22. https://doi.org/10.1038/clpt.2009.146 PMID: 19844223.

116. Rothstein MA. GINA at Ten and the Future of Genetic Nondiscrimination Law. Hastings Cent Rep. 2018; 48(3):5–7. Epub 2018/05/29. https://doi.org/10.1002/hast.847 PMID: 29806900.

117. Ram N, Guerrini CJ, McGuire AL. Genealogy databases and the future of criminal investigation. Science. 2018; 360(6393):1078–9. Epub 2018/06/09. https://doi.org/10.1126/science.aau1083 PMID: 29880677.

118. Chung W, Okur V, Appelbaum PS. Bioethics Forum Essay [Internet]. The Hastings Center, editor2018. [cited 2018]. Available from: https://www.thehastingscenter.org/want-police-snooping-dna/.

119. Public Health Service Act, 42 USC 241(d)(1)(E)(2018).

120. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016; 538(7624):161–4. Epub 2016/10/14. https://doi.org/10.1038/538161a PMID: 27734877; PubMed Central PMCID: PMC5089703.

121. Condit CM. How the public understands genetics: non-deterministic and non-discriminatory interpretations of the “blueprint” metaphor. Public Understanding of Science. 2016.

122. Bates BR, Lynch JA, Bevan JL, Condit CM. Warranted concerns, warranted outlooks: a focus group study of public understandings of genetic research. Social science & medicine. 2005; 60(2):331–44.

123. Department of Homeland Security ea. Federal Policy for the Protection of Human Subjects. Federal Register; 2017. p. 82(12):7149–274. PMID: 28106360

124. Husedzinovic A, Ose D, Schickhardt C, Frohling S, Winkler EC. Stakeholders’ perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet. 2015; 23(12):1607–14. Epub 2015/03/05. https://doi.org/10.1038/ejhg.2015.27 PMID: 25735479; PubMed Central PMCID: PMC5089703.

125. Jamal L, Sapp JC, Lewis K, Yanes T, Facio FM, Biesecker LG, et al. Research participants’ attitudes towards the confidentiality of genomic sequence information. Eur J Hum Genet. 2014; 22(8):964–8. https://doi.org/10.1038/ejhg.2013.276 PMID: 24281371; PubMed Central PMCID: PMC4350593.

126. Khan A, Capps BJ, Sum MY, Kuswanto CN, Sim K. Informed consent for human genetic and genomic studies: a systematic review. Clinical Genetics. 2014; 86(3):199–206. https://doi.org/10.1111/cge.12384 PubMed PMID: WOS:000340892300001; PubMed Central PMCID: PMC3838341.

127. Chan TW, Mackey S, Hegney DG. Patients’ experiences on donation of their residual biological samples and the impact of these experiences on the type of consent given for the future research use of the tissue: a systematic review. International journal of evidence-based healthcare. 2012; 10(1):9–26. Epub 2012/03/13. https://doi.org/10.1111/j.1744-1609.2011.00251.x PMID: 22405414; PubMed Central PMCID: PMC3423390.

128. Goldsmith L, Jackson L, O’Connor A, Skirton H. Direct-to-consumer genomic testing: systematic review of the literature on user perspectives. European Journal of Human Genetics. 2012; 20(8):811–6. https://doi.org/10.1038/ejhg.2012.18 PubMed PMID: WOS:000306556600004; PubMed Central PMCID: PMC3923390.

129. Wai CT, Mackey SJ, Hegney DG. Patients’ experiences towards the donation of their residual biological samples and the impact of these experiences on the type of consent given for secondary use: A systematic review. JBI Libr Syst Rev. 2011; 9(42):1714–81. Epub 2011/01/01. PMID: 27820581.